Gold has topped $4,200. Here’s why Yardeni thinks the rally could go even higher.
Ligand Pharmaceuticals Incorporated stock reached a 52-week high of $183.98, marking a significant milestone for the company. According to InvestingPro data, the company maintains strong financials with a current ratio of 5.45 and impressive revenue growth of 40.54% in the last twelve months. Over the past year, Ligand Pharmaceuticals has experienced a remarkable 78.08% increase in its stock value, reflecting strong investor confidence and positive market performance. This achievement underscores the company’s successful strategies and growth potential in the pharmaceutical sector. As Ligand continues to innovate and expand its portfolio, investors remain optimistic about its future prospects, with analysts setting a high target of $206. InvestingPro analysis suggests the stock is currently trading above its Fair Value, with 12 additional exclusive insights available to subscribers through the comprehensive Pro Research Report.
In other recent news, Ligand Pharmaceuticals has been the focus of several analyst upgrades and financial activities. The company recently completed a $460 million convertible notes offering, which included a full exercise of an option to purchase an additional $60 million in notes, resulting in net proceeds of approximately $445.1 million. This capital raise was followed by Oppenheimer increasing its price target for Ligand Pharma to $190, citing the lower weighted average cost of capital (WACC) from the capital raise. Benchmark also raised its price target to $175, attributing the increase to Ligand’s strong second-quarter 2025 earnings report. Additionally, H.C. Wainwright increased its price target to $206, following the FDA’s approval of an update to the REMS labeling for FILSPARI, which included changes to liver function and pregnancy monitoring requirements. These recent developments reflect significant financial maneuvers and positive analyst sentiment for Ligand Pharmaceuticals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.